Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

A Ligandable PNT Domain Establishes ERG As a Directly Targetable Oncogenic Driver in Prostate Cancer

July 24, 2026

[Proceedings of the National Academy of Sciences of the United States of America] Investigators demonstrated continued dependency on ERG in metastatic prostate cancer and identify a druggable pocket within its N-terminal Pointed (PNT) domain.

ZNF263-NuRD-Mediated Repression of STAT1 Curtails MHC-I Antigen Presentation and IFN-γ Efficacy in Prostate Cancer

July 24, 2026

[Proceedings of the National Academy of Sciences of the United States of America] Researchers identified ZNF263 as a transcriptional repressor that silences MHC-I by recruiting nucleosome-remodeling and deacetylase (NuRD) to the STAT1 promoter, reducing STAT1 and MHC-I expression.

Randomized Phase II Trial of Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: The CheckPRO,...

July 24, 2026

[Journal for Immunotherapy of Cancer] Scientists hypothesized that the addition of stereotactic body radiation therapy could enhance immune responses and improve treatment outcomes.

A Novel lncRNA HUDRPC Suppresses Ferroptosis via the DDX5/DDIT3 Pathway to Promote Docetaxel Resistance in Prostate Cancer

July 24, 2026

[Cancer Letters] The authors functionally characterized a novel docetaxel resistance-associated lncRNA in prostate cancer. They identified an uncharacterized lncRNA, termed HUDRPC, which was significantly upregulated in resistant cells and patient-derived tumor tissues.

Adipose Triglyceride Lipase Driven Lipolysis As a Targetable Metabolic Vulnerability in Prostate Cancer with Intrinsic Metabolic Inflexibility

July 24, 2026

[British Journal of Cancer] ATGL-mediated lipolysis represents a promising therapeutic target in prostate cancer, with heightened sensitivity in tumours lacking metabolic flexibility to utilize alternative pathways.

METTL5-Mediated rRNA Modification Controls Prostate Cancer Progression through the IRF7/DNA2 Axis and Mitophagy Regulation

July 24, 2026

[Oncogene] Researchers showed that the rRNA m6A methyltransferase METTL5 was progressively upregulated during prostate cancer progression and was associated with poor patient survival.

Targeting the NR3C1-ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer

July 24, 2026

[Cancer Science] Scientists revealed that the nuclear receptor subfamily 3 group C member 1 (NR3C1)-acyl-CoA synthetase long-chain family member 4 (ACSL4) axis regulates lipid peroxidation and promotes radioresistance.

Development and Advantages of O-(Carboxymethyl)-L-Tyrosine-Based PSMA-Targeting Theranostics for Prostate Cancer

July 24, 2026

[Journal of Medicinal Chemistry] The authors highlight that PSMA-targeting agents incorporate the O-(carboxymethyl)-L-tyrosine scaffold, a versatile linker that enhances binding affinity and optimizes pharmacokinetics.

FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

July 24, 2026

[Pfizer, Inc.] Pfizer, Inc. announced that the US FDA accepted for Priority Review a supplemental New Drug Application for TALZENNA^®, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI^®, an androgen receptor pathway inhibitor, in men with homologous recombination repair gene-altered metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer.

BjöRn Gysell Is Donating to Research into Future Treatments for Prostate Cancer

July 10, 2026

[Karolinska Institutet] A prostate cancer research initiative in Sweden has been made possible by a donation from Björn Gysell. The investment will enable Karolinska Institutet’s research environment in prostate cancer to develop the next generation diagnostics and therapies using AI, genomics and precision medicine.

SETDB1-Mediated Repression of RhoB Promotes EMT and Metastatic Progression in Prostate Cancer

July 10, 2026

[Oncogene] Scientists identified SET domain bifurcated 1 (SETDB1) as a key regulator of epithelial–mesenchymal transition (EMT) and metastasis through direct repression of RhoB, the small GTPase. SETDB1 is genomically amplified and transcriptionally upregulated in metastatic CRPC.

Functional and Omics-Based Rationale for the Induction of BRCAness by Androgen Receptor Pathway Inhibitors to Sensitize Prostate Cancer to PARP Inhibition, Regardless of HRR...

July 10, 2026

[British Journal of Cancer] Researchers assessed poly (ADP‒ribose) polymerase (PARP) inhibitors alone and with androgen receptor pathway inhibitors in prostate cancer cell lines, metastatic patient-derived organoids, and LN-metastatic tissue slice cultures.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.